‘Hyalrheuma,’ Hanmi Pharm’s arthritis treatment acquires FDA approval
Hanmi Pharm(CEO Sae-Chang Kwon & Jong-Soo Woo) announced on the 9th that the company has acquired approval of ‘Hyalrheuma Inj,’ a self-developed arthritis treatment, from the U.S. FDA for the first time as a Korean company.
‘Hyalrheuma,’ a sodium hyaluronate injection developed using the company...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
